tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2016 Nov 4. [Epub ahead of print]
[h=1]Fluzone? High-Dose Influenza Vaccine.[/h] Robertson CA[SUP]1[/SUP], DiazGranados CA[SUP]1[/SUP], Decker M[SUP]1,[/SUP][SUP]2[/SUP], Chit A[SUP]1,[/SUP][SUP]3[/SUP], Mercer M[SUP]1[/SUP], Greenberg DP[SUP]1,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] Fluzone? High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 ?g hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-SD). IIV3-HD has been licensed for use in older adults in the US since December 2009 and in Canada since February 2016. Areas covered: In this review, we summarize post-licensure studies on the immunogenicity, safety, and effectiveness of IIV3-HD and estimates of its cost-effectiveness in older adults. We also discuss the potential application of IIV3-HD in adults 50-64 years of age and in individuals who may respond poorly to standard-dose influenza vaccines. Expert commentary: Multiple studies conducted since 2004 have consistently shown that, in older adults, IIV3-HD induces substantially greater antibody responses and better protection against influenza and influenza-associated hospitalization than IIV3-SD. Health economic analyses suggest that IIV3-HD can be a cost-effective alternative to standard-dose trivalent or quadrivalent inactivated influenza vaccines and can even be cost-saving compared to IIV3-SD in older adults. Further investigation of IIV3-HD vaccination as a way to improve immune responses and protection against influenza in immunocompromised individuals is warranted.
[h=4]KEYWORDS:[/h] Influenza; high-dose; immunocompromising conditions; immunosenescence; older adults; vaccine
PMID: 27813430 DOI: 10.1080/14760584.2016.1254044
[PubMed - as supplied by publisher]
[h=1]Fluzone? High-Dose Influenza Vaccine.[/h] Robertson CA[SUP]1[/SUP], DiazGranados CA[SUP]1[/SUP], Decker M[SUP]1,[/SUP][SUP]2[/SUP], Chit A[SUP]1,[/SUP][SUP]3[/SUP], Mercer M[SUP]1[/SUP], Greenberg DP[SUP]1,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] Fluzone? High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 ?g hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-SD). IIV3-HD has been licensed for use in older adults in the US since December 2009 and in Canada since February 2016. Areas covered: In this review, we summarize post-licensure studies on the immunogenicity, safety, and effectiveness of IIV3-HD and estimates of its cost-effectiveness in older adults. We also discuss the potential application of IIV3-HD in adults 50-64 years of age and in individuals who may respond poorly to standard-dose influenza vaccines. Expert commentary: Multiple studies conducted since 2004 have consistently shown that, in older adults, IIV3-HD induces substantially greater antibody responses and better protection against influenza and influenza-associated hospitalization than IIV3-SD. Health economic analyses suggest that IIV3-HD can be a cost-effective alternative to standard-dose trivalent or quadrivalent inactivated influenza vaccines and can even be cost-saving compared to IIV3-SD in older adults. Further investigation of IIV3-HD vaccination as a way to improve immune responses and protection against influenza in immunocompromised individuals is warranted.
[h=4]KEYWORDS:[/h] Influenza; high-dose; immunocompromising conditions; immunosenescence; older adults; vaccine
PMID: 27813430 DOI: 10.1080/14760584.2016.1254044
[PubMed - as supplied by publisher]